While demand for clinical services has recovered from its dip, preclinical interest is still weak and is likely to remain so.???Most agree that the industry is not merely going through a prolonged cyclical slowdown, but has also structurally changed, with less of an emphasis by clients on maximising the number of drug candidates flowing into preclinical testing???, John Kreger, equity analyst at W